S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

$0.22
0.00 (0.00%)
(As of 02/23/2024 ET)
Today's Range
$0.19
$0.23
50-Day Range
$0.22
$0.52
52-Week Range
$0.19
$2.08
Volume
347,165 shs
Average Volume
152,004 shs
Market Capitalization
$17.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Akili MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,705.1% Upside
$4.00 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Akili in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.02 out of 5 stars

Medical Sector

379th out of 942 stocks

Surgical & Medical Instruments Industry

48th out of 90 stocks


AKLI stock logo

About Akili Stock (NASDAQ:AKLI)

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.

AKLI Stock Price History

AKLI Stock News Headlines

CEO of America's biggest bank has stern warning
CEO of America’s biggest bank says, “I’m not sure if the world is prepared” for what he believes is coming next.
Short Interest in Akili, Inc. (NASDAQ:AKLI) Decreases By 24.0%
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Akili Inc Ordinary Shares
Akili Inc Ordinary Shares AKLI
Akili, Inc. (NASDAQ:AKLI) Q3 2023 Earnings Call Transcript
Akili Announces Leadership Transition
Akili, Inc. reports Q2 results
See More Headlines
Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2023
Today
2/25/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AKLI
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,705.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,960,000.00
Net Margins
-6,265.48%
Pretax Margin
-6,263.65%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$1.42 per share

Miscellaneous

Free Float
62,335,000
Market Cap
$17.35 million
Optionable
Optionable
Beta
1.78
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Walter Edward Martucci II (Age 42)
    Ph.D., Co-Founder & Chairman
    Comp: $654.36k
  • Mr. Matthew Franklin M.B.A. (Age 50)
    President, CEO & Director
    Comp: $506.39k
  • Dr. Adam Gazzaley M.D. (Age 55)
    Ph.D., Co-Founder, Chief Science Advisor & Director
    Comp: $100k
  • Ms. Jacqueline L. Studer J.D. (Age 65)
    Chief Legal Officer, General Counsel & Secretary
    Comp: $512.7k
  • Ms. Caty Reid
    VP of Marketing & Communications
  • Dr. Scott H. Kollins Ph.D.
    Chief Medical Officer
  • Mr. Jonathan David (Age 46)
    Chief Product Officer














AKLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Akili stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akili in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKLI shares.
View AKLI analyst ratings
or view top-rated stocks.

What is Akili's stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price objectives for Akili's shares. Their AKLI share price targets range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 1,705.1% from the stock's current price.
View analysts price targets for AKLI
or view top-rated stocks among Wall Street analysts.

How have AKLI shares performed in 2024?

Akili's stock was trading at $0.4871 at the start of the year. Since then, AKLI stock has decreased by 54.5% and is now trading at $0.2216.
View the best growth stocks for 2024 here
.

Are investors shorting Akili?

Akili saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 61,900 shares, a decline of 24.0% from the January 15th total of 81,500 shares. Based on an average daily volume of 133,400 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.2% of the shares of the company are short sold.
View Akili's Short Interest
.

When is Akili's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our AKLI earnings forecast
.

How were Akili's earnings last quarter?

Akili, Inc. (NASDAQ:AKLI) announced its earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.11 million for the quarter. Akili had a negative net margin of 6,265.48% and a negative trailing twelve-month return on equity of 76.97%.

Who are Akili's major shareholders?

Akili's stock is owned by a variety of institutional and retail investors. Top institutional investors include StoneX Group Inc. (1.36%), Longitude Cayman Ltd. (0.26%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jacqueline Studer, Matthew Franklin, Santosh Shanbhag and Walter Edward Martucci II.
View institutional ownership trends
.

How do I buy shares of Akili?

Shares of AKLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKLI) was last updated on 2/25/2024 by MarketBeat.com Staff